JLJunxi Liu

Junxi Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junxi Liu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Duolong Di

    Chinese Academy of Sciences Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, China

    6 shared publications
  • Mei Zhong

    Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province

    4 shared publications
  • Qian Yan

    CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou 730000, PR China; University of Chinese Academy of Sciences, Beijing 10049, PR China

    4 shared publications
  • Aiyi Xin

    Chinese Academy of Sciences Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, China; University of Chinese Academy of Sciences, Beijing, 10049, China

    3 shared publications
  • Yali Chen

    Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province

    3 shared publications
  • Yanxia Zhang

    Chinese Academy of Sciences Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, China; University of Chinese Academy of Sciences, Beijing, 10049, China

    3 shared publications

Latest Publications

  • Open Access

    A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the FPR1/NLRP3 Signaling Axis

    by Juan Gao, Gang Su, Jifei Liu, Jinyang Song, Wei Chen, Miao Chai, Xiaodong Xie, Manxia Wang, Junxi Liu, Zhenchang Zhang

    Background: Microglia/macrophages, as pivotal immune cells in the central nervous system (CNS), play a critical role in neuroinflammation associated with ischemic brain injury. Targeting their activation through pharmacological interventions represents a promising strategy to alleviate neurological deficits, thereby harboring significant implications for the prevention and treatment of ischemic stroke. Ligusticum cycloprolactam (LIGc), a novel monomeric derivative of traditional Chinese medicine, has shown potential as a therapeutic agent; however, its specific role in cerebral ischemic injury remains unclear.Methods: In vitro experiments utilized lipopolysaccharide (LPS)‐induced inflammation models of RAW264.7 cells and primary mouse microglia. In vivo studies employed LPS‐induced neuroinflammation models in mice and a transient middle cerebral artery occlusion (tMCAO) mouse model to evaluate the impact of LIGc on neuroinflammation and microglia/macrophage phenotypic alterations. Further elucidation of the molecular mechanisms underlying these effects was achieved through RNA‐Seq analyses.Results: LIGc exhibited the capacity to attenuate LPS‐induced production of pro‐inflammatory markers in macrophages and microglia, facilitating their transition to an anti‐inflammatory phenotype. In models of LPS‐induced neuroinflammation and tMCAO, LIGc ameliorated pathological behaviors and neurological deficits while mitigating brain inflammation. RNA‐seq analyses revealed formyl peptide receptor 1 (FPR1) as a critical mediator of LIGc's effects. Specifically, FPR1 enhances the pro‐inflammatory phenotype of microglia/macrophages and inhibits their anti‐inflammatory response by upregulating NLR family pyrin domain protein 3 (NLRP3) inflammasomes, thus aggravating inflammatory processes. Conversely, LIGc exerts anti‐inflammatory effects by downregulating the FPR1/NLRP3 signaling axis. Furthermore, FPR1 overexpression or NLRP3 agonists reversed the effects of LIGc observed in this study.Conclusion: Our findings suggest that LIGc holds promise in improving ischemic brain injury and neuroinflammation through modulation of microglia/macrophage polarization. Mechanistically, LIGc attenuates the pro‐inflammatory phenotype and promotes the anti‐inflammatory phenotype by targeting the FPR1/NLRP3 signaling pathway, ultimately reducing inflammatory responses and mitigating neurological damage.


  • Pharmacokinetics, tissue distribution, and safety evaluation of a ligustilide derivative (LIGc)

    by Yanxia Zhang, Yaming Zhang, Yanming Han, Ye Tian, Pengcheng Wu, Aiyi Xin, Xiaoning Wei, Yanbin Shi, Zhenchang Zhang, Gang Su, et al.


  • Development of an HPLC‐DAD method for the determination of five alkaloids in Stephania yunnanensis Lo and in rat plasma after oral dose of Stephania yunnanensis Lo extracts

    by Aiyi Xin, Yaming Zhang, Yanxia Zhang, Duolong Di, Junxi Liu

    For the rational utilization and the quantitative quality control of the Stephania yunnanensis Lo, an HPLC‐DAD method was developed for the quantitative and simultaneous determination of five alkaloids in rat plasma (stepharine, sinomenine, palmatine, isocorydine and tetrahydropalmatine), which were the main active chemical constituents of this plant and belong to four kinds of isoquinoline‐type alkaloids (protoberberine, morphine, aporphine and protaporphine alkaloids). The contents of five alkaloids ranged from 0.09 to 2.32% (w/w). The method validation was tested for the linearity (r2 > 0.9975), precision (intra‐day RSD < 4.8% and inter‐day RSD < 4.9%), extraction recovery (85.49 ± 2.29% to 99.21 ± 1.48%) and stability (98.5 ± 5.3% to 101.2 ± 3.4%). We developed an HPLC‐DAD method to simultaneously measure these alkaloids in rat plasma after oral administration of the extract of this plant to rats. The results supported the hypothesis that isoquinoline alkaloids were the compounds responsible for the main pharmacological activities for anti‐inflammatory and analgesic.


  • Design, synthesis, and anticancer properties of isocorydine derivatives

    by Qian Yan, Ruxia Li, Aiyi Xin, Yin Han, Yanxia Zhang, Junxi Liu, Wenguang Li, Duolong Di


  • Total content determination for the effective fraction of the alkaloids in Dicranostigma leptopodum (Maxim.) Fedde by HPLC and ultraviolet-visible spectrophotometry

    by Yali Chen, Ruxia Li, Rongrong Gao, Qian Yan, Mei Zhong, Junxi Liu, Quanyi Zhao, Duolong Di

    For the quality control and the rational use of the effective fraction of the alkaloids (EFA) in Dicranostigma leptopodum (Maxim.) Fedde (DLF), extraction and determination methods for EFA were developed in the present study. The purification of EFA was carried out on the D101 macroporous resin. The high-performance liquid chromatography with the diode-array detection (HPLC-DAD) method was established to determine the total alkaloid content of EFA. In this method, 0.4% ionic liquid (1-butyl-3-methylimidazole tetrafluoroborate) was added into the mobile phase as the tailing-suppression reagent. 5-hydroxy-coptisine, isocorytuberine, protopine, allocryptopine, coptisine, berberine, corydine, and isocorydine were selected as reference standards for the determination, and the total alkaloid content was calculated as their sum in EFA. The results suggested that the total alkaloid content of EFA was 19.04 ± 1.23% (n = 3). Since corresponding reference standards for the alkaloids of DLF are lacking, ultraviolet-visible (UV-Vis) spectrophotometry was also developed for the determination of the total alkaloid content of EFA. In this method, isocorydine was selected as the reference compound for the determination of the total alkaloid content and the results suggested that the total alkaloid content of EFA was 65.92 ± 1.33% (n = 3). These newly established methods were rapid and accurate with high repeatability, and can be applied for the further use of EFA in DLF.


  • Open Access

    Study on pharmacokinetics and tissue distribution of the isocorydine derivative (AICD) in rats by HPLC-DAD method

    by Yali Chen, Qian Yan, Mei Zhong, Quanyi Zhao, Junxi Liu, Duolong Di, Jinxia Liu


  • Simultaneous determination of the content of isoquinoline alkaloids in Dicranostigma leptopodum (Maxim) Fedde and the effective fractionation of the alkaloids by high‐performance liquid chromatography with diode array detection

    by Yali Chen, Min Li, Jianjun Liu, Qian Yan, Mei Zhong, Junxi Liu, Duolong Di, Jinxia Liu

    A simple and efficient method was developed for the simultaneous determination of eight isoquinoline alkaloids in methanol extracts of Dicranostigma leptopodum (Maxim) Fedde and the effective fractionation of the alkaloids of D. leptopodum by high‐performance liquid chromatography with diode array detection. The chromatographic conditions were optimized on a SinoChrom ODS‐BP column to obtain a good separation of the four types of alkaloid analytes, including two aporphines (isocorydine, corydine), two protopines (protopine and allocryptopine), a morphine (sinoacutine), and three quaternary protoberberine alkaloids (berberrubine, 5‐hydroxycoptisine, and berberine). The separation of these alkaloids was significantly affected by the composition of the mobile phase, and particularly by its pH value. Acetonitrile (A) and 0.2% phosphoric acid solution adjusted to pH 6.32 with triethylamine (B) were selected as the mobile phase with a gradient elution. With this method, a new quaternary protoberberine alkaloid was isolated and the two structural isomers (isocorydine and corydine) were baseline separated. The appropriate harvest period for D. leptopodum was also recommended based on our analysis. The method for the effective fraction of the alkaloids of D. leptopodum was optimized under this method with regard to the varying significant pharmacological activities of the alkaloids.


  • Open Access

    Isocorydine Derivatives and Their Anticancer Activities

    by Mei Zhong, Yanjuan Liu, Junxi Liu, Duolong Di, Mengrou Xu, Yaya Yang, Wenguang Li, Yali Chen, Jinxia Liu

    In order to improve the anticancer activity of isocorydine (ICD), ten isocorydine derivatives were prepared through chemical structure modifications, and their in vitro and in vivo activities were experimentally investigated. 8-Amino-isocorydine (8) and 6a,7-dihydrogen-isocorydione (10) could inhibit the growth of human lung (A549), gastric (SGC7901) and liver (HepG2) cancer cell lines in vitro. Isocorydione (2) could inhibit the tumor growth of murine sarcoma S180-bearing mice, and 8-acetamino-isocorydine (11), a pro-drug of 8-amino-isocorydine (8), which is instable in water solution at room temperature, had a good inhibitory effect on murine hepatoma H22-induced tumors. The results suggested that the isocorydine structural modifications at C-8 could significantly improve the biological activity of this alkaloid, indicating its suitability as a lead compound in the development of an effective anticancer agent.


  • A new quaternary protoberberine alkaloid isolated fromDicranostigma leptopodum(Maxim) Fedde

    by Mei Zhong, Yu-Xi Ma, Jun-Xi Liu, Duo-Long Di

    Phytochemical investigation of the whole plants of Dicranostigma leptopodum (Maxim) Fedde has led to the isolation of two quaternary protoberberine alkaloids 5-hydroxy-coptisine (1) and berberrubine (2). This type of alkaloids was isolated from the genus Dicranostigma for the first time and the new compound structure (1) was elucidated by various spectroscopic methods including 2D NMR techniques (gCOSY, HMQC and HMBC) and HR-ESI-MS.